Skip to content
Company Analysis

Baird Medical Investment Holdin BDMD

A comprehensive view of key metrics, scores, and financial health for Baird Medical Investment Holdin

Overview of Baird Medical Investment Holdings Limited

BDMD NCM
Healthcare Medical Devices Framework: Medical Devices & Diagnostics Micro Cap
Baird Medical Investment Holdings Limited (BDMD), is a Micro Cap company, in the Medical Devices industry, last closed at $1.12, about 0.0% overvalued vs fair value, -54.3% 1Y return, ranked 873/1145 in sector.
Metrics Rev Growth -39.2% ROE -76.8% Gross Margin 83.8%
USD 1.12
1.82%
(Delayed)
• Vol 90d: 61.5%
52-Week Range
Market Cap
$35.12M
Enterprise Value
$54.24M
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Fair
Health
Weak
Efficiency
Fair
Valuation
Weak
Growth
Weak
Profitability
Fair
Health
Weak
Efficiency
Fair
Valuation
Weak
Completeness: 100%
Confidence: 62%
Updated: Sep 12
Top Beats

Quick Facts

Website https://bairdmed.com
HQ Guangzhou
Employees 143
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$0
$0
$0
Current: $1.12

Engine Room Money Flow™

Micro Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$22.5M
-39.2%%
Gross Profit
$18.9M
-42.2%%
Operating Income (GAAP)
$-25.5M
-266.7%%
EBITDA
$-24.5M
-255.2%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
83.8%
Excellent

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
0/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Baird Medical Investment Holdin's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
46
/100
Developing
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Elite Gross Margins Gross margin quality is top-tier vs peers (score 0.93). This signals strong consumable attach-rate economics.
  • Above-Peer Asset Productivity Asset productivity is strong vs peers (score 0.96). Above-peer ROA underpins the growth durability narrative.

Key risks

  • Weak Capital Return Profile Capital return quality is below peers (score 0.29). Low ROIC raises questions about M&A discipline and pipeline ROI.
  • Below-Peer Operating Margin Operating margin level is below peers (score 0.27). SG&A leverage needs improvement to close the gap.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Strong
77
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing BDMD's balance between Growth (23.8%), Profitability (43.8%), and Safety (32.4%). Growth 24% Safety 32% Profitability 44%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

28th percentile vs peers
28
Key Signals
EPS Growth YoY 38.3% 61p EPS CAGR 3Y 13.1% 56p Revenue CAGR 3Y -13.7% 14p Rev Growth YoY -39.1% 9p Asset Growth YoY -10.6% 27p
Strengths
  • Gross Profit Margin in top 20% of peers (83.8%, 91th percentile)
Risks
  • Rev Growth YoY in bottom 20% of peers (-39.1%)

Profitability

52th percentile vs peers
52
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

38th percentile vs peers
39
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Baird Medical Investment Holdin.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-0.20
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000